Summary Coumarins inhibit metastasis in a number of animal models, but the mechanism of this effect remains unclear. We have investigated the relationship between the coagulation system and metastasis using a new model system, involving i.v. injection of Mtln3 rat mammary carcinoma cells into Fischer 344 rats, and subsequent estimation of pulmonary seeding.
There is extensive evidence from both clinical and experimental studies for an interaction between the coagulation system and the spread and growth of malignant disease (Wood, 1958; O'Meara, 1968; Hilgard et al., 1977; Zacharski et al., 1979; Dvorak et al., 1981) . Patient studies have demonstrated the existence of marked subclinical disturbances of the coagulation system in nearly all cancer patients (Sun et al., 1979; Rickles & Edwards, 1983; Mannuci et al., 1985) , whilst animal experiments have suggested that the coagulation system may play an important role in the pathogenesis of blood borne metastasis (Koike, 1964; Agostino et al., 1966; Brown, 1973; Wood, 1974; . The most striking and consistent finding in such animal experimentation has been the antimetastatic effect of the coumarin group of anticoagulant drugs in a variety of tumour/host combinations (Ryan et al., 1969; Hilgard & Maat, 1979; Williamson et al., 1980) . The coumarins mediate their anticoagulant activity by antagonising the action of vitamin K, an essential cofactor in the hepatic synthesis of the coagulation factors II (prothrombin), VII, IX and X (Stenflo & Suttie, 1977) . We have demonstrated that warfarin, a member of the coumarin group, inhibits metastasis in a model system comprising the Mtln3 rat mammary carcinoma clone and the syngeneic Fischer 344 rat, both when intravenous injection of the cells is employed and in the more realistic model involving spontaneous metastasis (McCulloch & George, 1987) . In addition, we showed that warfarin has no important cytotoxic effects for these tumour cells, that it inhibits metastasis principally by its effects on the host animal, and that the inhibition of metastasis is reversed by replenishment of the coagulation factors which warfarin suppresses. The exact role of these factors in the metastatic process therefore merited further study. The present studies were designed to determine whether the previously studied factor complex, or parts of it, could enhance metastasis in normal rats, and if so, whether this enhancing effect was dependent on a normal capacity to form fibrin. (Neri et al., 1982) from the 7,12-dimethylbenz(a)anthraceneinduced adenocarcinoma 13762 (Segaloff, 1966 Wexler (1966) . This entails inflation of the lungs via the trachea with a 15% solution of india ink, followed by fixation in Fekete's solution for at least 48h. Surface pulmonary tumour nodules can then be identified and counted accurately. All specimens were counted on two occasions by a single observer, who was unaware of the treatment given. No animal received treatment with warfarin or any other anticoagulant. In all groups receiving some form of treatment (Groups B-E) the first intravenous injection was given at the same time as the tumour cells, and the second 6 h later. The dose of bovine serum albumin used was 30mg in 0.6ml of F10/DMEM; this gave the same protein concentration as the factor complex injection in Group B rats. Bovine serum albumin and factor complex preparations were passed through a 0.2,um filter before injection, for sterilization and removal of any potentially embolic material. Comparison of the numbers of seedlings per set of lungs in the different groups was performed by Mann-Whitney U test. Analysis of procoagulant activity of tumour cells Mtln3 cells were trypsinised and washed in F10/DMEM as described above, resuspended in FIO/DMEM (without FCS), counted and adjusted to a cell density of 8 x 106 ml. This suspension (0.1 ml) was added to 0.1 ml of citrated plasma and 0.1 ml of CaCl2 (0.25 M) at 37°C and the clotting time of the mixture recorded electronically using a Dade fibrometer. The procedure was carried out in triplicate with normal human plasma and with bovine plasma deficient in factor VII (factor VII DBP) and in both factors VII (Table III) . Activities are expressed as a percentage of the clotting time obtained using pooled normal human plasma. Results represent the mean of triplicate assays performed on at least two occasions. Within assay variation was < 10%.
Discussion
The experiments described in this paper demonstrate contrasting effects on metastasis of two different manipulations of the coagulation system. In order to interpret the results correctly, it is important to understand clearly the effect on coagulation of the treatments used.
The injection of an excess of coagulation factors into animals whose coagulation was already optimal did not appear to produce excessive or supranormal coagulation, as measured by thrombotest estimation. This result demonstrated that the preparations used had no significant content of activated factors. It is therefore unlikely that the striking effect of factor complex injections on metastasis can be explained by a major effect on the activity of the coagulation system. Arvin removes fibrinogen from the circulation by cleaving fibrinopeptide A from the molecule; this produces an inactive monomer, des-A-fibrinogen, which is rapidly cleared by the reticuloendothelial and fibrinolytic systems (Bell et al., 1978) . Arvin effectively reduced plasma fibrinogen concentration of our animals by nearly 70% at the time of tumour cell injection. This is roughly equivalent to a reduction of fibrin forming capacity of the same amount. The dose used was chosen to avoid causing any significant circulatory disturbance. Preliminary experiments showed that rats could tolerate very high doses of arvin, but that above 300 IU kg-1, significant toxic effects could be observed during i.v. injection. Half of this dose was therefore used in the present experiment. The level of defibrination achieved was similar to the target range in humans when the drug is used clinically as an anticoagulant.
The results of our two experiments can now be summarised. First, injection of the coagulation factors II, VII, IX and X into normal rats greatly enhances the metastasis of tumour cells injected at the same time; second, this effect persists if factor VII is omitted from the complex, whilst this factor alone has no discernible effect=on metastasis. Third, a very significant reduction in fibrin forming capacity has no discernible effect on metastasis. Finally, this degree of reduction in fibrin forming capacity does not diminish the enhancing effect on metastasis of the II, VII, IX and X factor complex. These findings indicate that some component of the II, IX and X complex is capable of greatly enhancing metastasis. They also suggest that this enhancing effect may not be dependent on the formation of fibrin. These conclusions are consistent with the results of our previous studies, and with reports (Hagmar, 1972; Donati et al., 1978) , that defibrinating agents have no consistent effect on metastasis in other models.
bne animal in group B and two animals in group C died from the effects of repeated ether anaesthesia. The results in these two groups are therefore calculated on 9 and 8 animals respectively. aIndicates P <0.01 (Mann-Whitney U test for group results against control group).
Complete defibrination cannot be achieved with arvin in this model, and it is therefore possible that enough fibrin remains after arvin treatment to fulfil a vital role in enhancing metastasis. However the very marked reduction in metastasis achieved with coumarin anticoagulant treatment (Ryan et al., 1969; Brown, 1973; Hilgard et al., 1978; Poggi et al., 1978; McCulloch & George, 1987) is in striking contrast with the complete absence of any such reduction following arvin treatment. If the formation of a fibrin clot is essential to the metastasis-enhancing process, it is surprising that two major suppressive influences on coagulation should have such contrasting results. Conversely, the marked enhancement of metastasis achieved in normal animals by injecting coagulation factors is unlikely to be due to enhanced coagulation activity, since this could not be detected. Further work is required to confirm our findings, but the evidence of these studies is in favour of a potentiating mechanism which involves specific coagulation factors, rather than coagulation as a whole.
Certain tumour cells have been shown to produce a vitamin K dependent cysteine protease procoagulant (CP) which directly activates factor X (Gordon et al., 1975) , and which may be implicated in the process of metastasis (Colucci et al., 1983) . Such a molecule might be activated by injections containing factor X, and a modification of the method of Gordon was therefore used to measure the procoagulant capacity of cultured Mtln3 cells. We have previously shown that warfarin treatment of Mtln3 cells prior to injection into a host animal does not affect their metastatic behaviour, and this makes it unlikely that CP plays a major role in the metastatic process in this model. Direct in vitro analysis of the procoagulant properties of Mtln3 cells shows that the component of total procoagulant activity which appears to be dependent on factor X (but not factor VII) is not predominant, and is unaffected by warfarin treatment of the cells. These results are similar to those obtained using non-malignant cell lines, and suggest that Mtln3 contains little or no CP.
Our previous results, and those of others (Brown, 1973; McCulloch & George, 1987) , suggest that the antimetastatic effect of warfarin probably occurs within the first few hours after tumour cells enter the bloodstream. The model we have adopted allows this part of the metastatic process to be studied closely, whilst eliminating the influence of changes in the primary tumour: It has also enabled us to design useful experiments which would not have been possible in a more complete model of metastasis. The use of a small number of cells from a genuinely metastatic neoplasm minimised the risk, which arises in such models (Poggi et al., 1981) of artefacts caused by effects of the cell injection on the coagulation and immune systems, and on the lung vasculature.
The mechanism by which the factors II, IX and X complex enhances metastasis cannot be deduced from this work. Interactions between certain coagulation factors, notably factor XII and other biological systems such as the complement system, the kinin system, fibrinolysis and platelet activation are known to occur (Zimmerman et al., 1977) , and the metastasis-enhancing effect may be mediated via a similar mechanism. Our findings must cast doubt on many of the commonly proposed theories for the interaction of cancer with coagulation, which have assumed that the interaction occurs at the level of fibrin clot formation (Zacharski, 1984) . If confirmed by further studies, these results will require the formulation of quite different theories of the cancer/coagulation relationship. The finding that intravenous injection of coagulation factors enhances metastasis may, if it can be shown to extend to the human situation, have implications for the current controversy on the effects of perioperative blood transfusion on survival in cancer patients.
